Akeso's ligufalimab combination achieves deep responses in frontline AML at EHA 2026
June 18, 2026 | 10:33
Akeso has announced compelling Phase II trial results for ligufalimab in combination therapy for frontline acute myeloid leukemia, presented as an oral presentation at the European Hematology Association 2026 Congress.
Akeso's first bispecific ADC enters clinical trials, advancing ‘IO+ADC’ 2.0 strategy
July 04, 2025 | 13:00
The Trop2/Nectin4 bispecific drug reinforces Akeso’s pipeline of next-generation oncology treatments.
Latest News
Mobile Version